Shaun Goodyear

ORCID: 0000-0003-0217-0890
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Reproductive Biology and Fertility
  • Pancreatic and Hepatic Oncology Research
  • Cancer Genomics and Diagnostics
  • Sperm and Testicular Function
  • Advanced Breast Cancer Therapies
  • Cancer Immunotherapy and Biomarkers
  • Cancer Cells and Metastasis
  • Advanced biosensing and bioanalysis techniques
  • PARP inhibition in cancer therapy
  • Colorectal Cancer Treatments and Studies
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Gut microbiota and health
  • Prostate Cancer Treatment and Research
  • RNA Interference and Gene Delivery
  • Cancer-related Molecular Pathways
  • HER2/EGFR in Cancer Research
  • Pluripotent Stem Cells Research
  • Chronic Lymphocytic Leukemia Research
  • Cancer Treatment and Pharmacology
  • TGF-β signaling in diseases
  • Nanoparticle-Based Drug Delivery
  • Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
  • Cancer-related molecular mechanisms research
  • Advanced Biosensing Techniques and Applications
  • Renal cell carcinoma treatment

Oregon Health & Science University
2014-2025

OHSU Knight Cancer Institute
2017-2024

University of Portland
2024

Oregon Medical Research Center
2021

Cancer Institute (WIA)
2017

University of Pennsylvania
2011-2016

Drexel University
2006-2012

State Key Laboratory of Reproductive Medicine
2012

Hua Medicine (China)
2012

MicroRNAs (miRs) play a key role in the control of gene expression wide array tissue systems, where their functions include regulation self-renewal, cellular differentiation, proliferation, and apoptosis. However, functional importance individual miRs controlling spermatogonial stem cell (SSC) homeostasis has not been investigated. Using high-throughput sequencing, we profiled Thy1 + testis population, which is highly enriched for SSCs, − composed primarily somatic cells. In addition, global...

10.1073/pnas.1109987108 article EN Proceedings of the National Academy of Sciences 2011-07-18

In vivo delivery of siRNAs designed to inhibit genes important in cancer and other diseases continues be an biomedical goal. A new nanoparticle construct that is engineered for efficient siRNA tumors now described. The comprises a 47‐nm mesoporous silica core coated with crosslinked polyethyleneimine–polyethyleneglycol copolymer, carrying against the human epidermal growth factor receptor type 2 (HER2) oncogene, coupled anti‐HER2 monoclonal antibody (trastuzumab). increase blood half‐life,...

10.1002/adfm.201404629 article EN Advanced Functional Materials 2015-03-24

BACKGROUNDApproximately 80% of childhood cancers can now be cured but a side effect treatment results in about one-third the surviving boys being infertile or severely subfertile when they reach reproductive age. Currently, more than 1 5000 men age who are cancer survivors suffer from this serious quality life problem. It is possible to obtain testicular biopsy before preserve spermatogonial stem cells (SSCs) male by cryopreservation, long-term storage SSCs on their subsequent functional...

10.1093/humrep/des077 article EN Human Reproduction 2012-03-12

Insight regarding mechanisms controlling gene expression in the spermatogonial stem cell (SSC) will improve our understanding of processes regulating spermatogenesis and aid treating problems associated with male infertility. In present study, we explored global profiles glial line-derived neurotrophic factor (GDNF)-regulated transcription factors Ets (E-twenty-six) variant 5 (Etv5); B-cell chronic lymphocytic leukemia (CLL)/lymphoma 6, member B (Bcl6b); POU domain, class-3 1 (Pou3f1). We...

10.1095/biolreprod.111.091793 article EN Biology of Reproduction 2011-08-05

Prior studies describing the treatment of symptomatic knee osteoarthritis with injections bone marrow concentrate have provided encouraging results. The relationship between cellular dose contained within and efficacy treatment, however, is unclear. In present study we describe clinical outcomes for in relation to higher lower cell concentrations a protocol. Data from an ongoing patient registry was culled identify 373 patients that received 424 osteoarthritic joints. scales these were...

10.1186/s12891-015-0714-z article EN cc-by BMC Musculoskeletal Disorders 2015-09-18

Shoulder pain is a common musculoskeletal complaint in the general population. Bone marrow concentrate (BMC) injections offer promising potential as minimally invasive approach for treatment of shoulder degenerative disease. In this study, we investigated clinical outcomes BMC and disability due to osteoarthritis (OA) rotator cuff tears registry population.A total 115 shoulders 102 patients were treated with autologous symptomatic OA at glenohumeral joint and/or tears. Data collected factors...

10.2147/jpr.s80872 article EN cc-by-nc Journal of Pain Research 2015-06-01

We have developed a thiol-modified nanoporous silica material (SH-SAMMS) as an oral therapy for the prevention and treatment of heavy metal poisoning. SH-SAMMS has been reported to be highly efficient at capturing metals in biological fluids water. Herein, was examined efficacy safety both vitro vivo animal models detoxification metals. In simulated gastrointestinal fluids, had very high affinity (Kd) methyl mercury (MeHg(I)), inorganic (Hg(II)), lead (Pb(II)), cadmium (Cd(II)) superior...

10.1021/am5007707 article EN publisher-specific-oa ACS Applied Materials & Interfaces 2014-03-24

Abstract Identifying triple negative breast cancer (TNBC) patients expected to have poor outcomes provides an opportunity enhance clinical management. We applied Evolutionary Action Score functionally characterize TP53 mutations (EAp53) in 96 TNBC and observed that EAp53 stratification may identify associated with worse outcomes. These findings merit further exploration larger cohorts treated neoadjuvant chemotherapy regimens.

10.1038/s41698-022-00303-6 article EN cc-by npj Precision Oncology 2022-09-09

Understanding the initial mechanisms by which epithelial cells transform to an invasive phenotype is critical development of diagnostics that can identify metastatic potential cancers as well therapeutic agents prevent metastases. Changes in cellular response transforming growth factor-beta (TGF-β) cytokine are known promote cell invasion and metastasis part through induction epithelial-mesenchymal transitions (EMTs). In this report, we demonstrate non-metastatic human prostate cancer lines...

10.1093/carcin/bgs227 article EN Carcinogenesis 2012-07-12

Abstract Background Cyclin-dependent kinase 4/6 inhibitors (CDKi) have changed the landscape for treatment of patients with hormone receptor positive, human epidermal growth factor 2-negative (HR+/HER−) metastatic breast cancer (MBC). However, next-line strategies after CDKi progression are not yet optimized. We report here impact clinical and genomic factors on post-CDKi outcomes in a single institution cohort HR+/HER2− MBC. Methods retrospectively reviewed medical records MBC that received...

10.1093/oncolo/oyad035 article EN cc-by The Oncologist 2023-03-22

Breast cancer (BCa) has many well-known risk factors, including age, genetics, lifestyle, and diet; however, the influence of gut microbiome on BCa remains an emerging area investigation. This study explores connection between microbiome, dietary habits, risk. We enrolled newly diagnosed patients age-matched cancer-free controls in a case-control study. Comprehensive patient data was collected, habits assessed through National Cancer Institute Diet History Questionnaire (DHQ). 16S rRNA...

10.3390/nu15214628 article EN Nutrients 2023-10-31

760 Background: Pancreatic adenosquamous carcinoma (PASC) is a rare histopathological type of pancreatic cancer that more aggressive than ductal adenocarcinoma (PDAC). Although PASC has unique tumor biology and poorer prognosis, there are no guidelines for differentially treating patients, its rarity makes it significantly understudied. We used Nanostring GeoMX digital spatial profiling (DSP) to provide targeted proteomic characterization key tumor-promoting proteins in PDAC. Methods: FFPE...

10.1200/jco.2025.43.4_suppl.760 article EN Journal of Clinical Oncology 2025-01-27

Abstract Background: First-line CDKi and endocrine therapy has improved survival for patients with mHRBC. Upon progression, the optimal treatment strategy mHRBC without a targetable mutation in PIK3CA, AKT, PTEN or ESR1 is unclear. The CAPItello-291 trial showed that targeting PIK3CA pathway after progression-free survival, including identifiable genomic alterations AKT PTEN. Protein expression analysis may identify whether signaling pathways such as PIK3CA/AKT are upregulated proffer...

10.1158/1538-7445.am2025-5341 article EN Cancer Research 2025-04-21

e13102 Background: First-line CDKi and endocrine therapy has improved survival for many patients (pts) with mHRBC. Yet, some pts still experience rapid disease progression within 6 months of initiation require a tailored therapeutic approach. To understand tumor microenvironment factors associated progression, we performed digital spatial protein profiling (DSP), RNA sequencing (RNAseq) multiplexed immunohistochemistry (mIHC) on samples collected from before after CDKi. Methods: We...

10.1200/jco.2025.43.16_suppl.e13102 article EN Journal of Clinical Oncology 2025-05-28

3602 Background: Total neoadjuvant therapy (TNT) with chemo-radiation (CRT) followed by doublet chemotherapy for rectal cancer can yield clinical complete response (CR) to allow successful surgery or organ-sparing. Trifluridine exhibited cytotoxic effect of ionizing radiation superior fluorouracil in colonogenic survival assay (dose modification factor: 2.7). The FIERCE trial (NCT04104139) sought determine the maximum tolerated dose (MTD) trifluridine/tipiracil (FTD-TPI) concurrent CRT...

10.1200/jco.2025.43.16_suppl.3602 article EN Journal of Clinical Oncology 2025-05-28

e12598 Background: Less than 20% of hormone receptor-positive HER2-negative breast cancer (HRBC) patients (pts) achieve pathologic complete response with current chemotherapy-based neoadjuvant treatment (NAT). There is a need to evaluate novel non-chemotherapy NAT regimens for HRBC. Abemaciclib cyclin dependent kinase 4/6 inhibitor approved the high-risk early stage and metastatic Niraparib poly-ADP-ribose polymerase (PARPi) ovarian cancers. In preclinical data, abemaciclib sensitizes tumors...

10.1200/jco.2025.43.16_suppl.e12598 article EN Journal of Clinical Oncology 2025-05-28

4190 Background: Neoadjuvant chemotherapy (NAC) for localized PDAC may improve R0 resection. FFX and GA are used but lack of predictive biomarkers remains a barrier to optimal NAC. The angiotensin-II receptor blocker (ARB), losartan, remodels vascular perfusion enhance NAC efficacy. We established an experimental platform dynamic switching +/- radiation therapy resectable/BR exploratory cohort LA PDAC. Methods: Patients (pts) received 4 cycles (ox 85 mg/m2; LV 400 iri 150 5-FU 2400 mg/m2),...

10.1200/jco.2025.43.16_suppl.4190 article EN Journal of Clinical Oncology 2025-05-28

4099 Background: TIM-3 is highly expressed in cancer and mediates T cell exhaustion/dysfunction that can be an important mechanism of immune escape. Cobolimab, anti-TIM-3 monoclonal antibody, combination with dostarlimab (a PD-1 inhibitor), has been shown to enhance T-cell activity preclinical assessments. This study aimed investigate the efficacy safety cobolimab treatment unresectable hepatocellular carcinoma (HCC). Methods: a multi-center, single-arm, phase II study. Eligible patients...

10.1200/jco.2025.43.16_suppl.4099 article EN Journal of Clinical Oncology 2025-05-28

The chemokine (C‐X‐C) receptor type 4 (CXCR4) is an early marker of primordial germ cells (PGCs) essential for their migration and colonization the gonads. In spermatogonial stem (SSCs), expression CXCR4 promoted by self‐renewal factor, glial cell line‐derived neurotrophic factor (GDNF). Here, we demonstrate important role during donor mouse SSCs reoccupation endogenous niche in recipient testis. Silencing dramatically reduced number cell‐derived colonies, whereas colony morphology...

10.1155/2016/5796305 article EN cc-by Stem Cells International 2016-01-01
Coming Soon ...